Antipsychotics Commonly Used Off-Label By Dementia Patients, AHRQ Finds
Executive Summary
About 25 percent of people with dementia living in either a community setting or long-term care facility receive cholinesterase inhibitors, a government-funded study found
You may also be interested in...
Omnicare Settlement With DoJ Shows Power Of Nursing Homes In Driving Rxs
Omnicare's settlement with the Department of Justice to resolve kickback allegations was remarkable for the breadth and complexity of the government's case. But it also cast attention on a particular segment of the pharmaceutical market: nursing homes
Omnicare Settlement With DoJ Shows Power Of Nursing Homes In Driving Rxs
Omnicare's settlement with the Department of Justice to resolve kickback allegations was remarkable for the breadth and complexity of the government's case. But it also cast attention on a particular segment of the pharmaceutical market: nursing homes
Boxed Warning For Antipsychotics First Public Use Of FDA Labeling Authority
FDA put its new labeling authority under the FDA Amendments Act on public display June 16 by directing makers of conventional antipsychotics to add to their drugs' prescribing information a boxed warning about use in elderly patients with dementia